HK1254835A1 - 葡萄糖攝取抑制劑 - Google Patents

葡萄糖攝取抑制劑

Info

Publication number
HK1254835A1
HK1254835A1 HK18113929.9A HK18113929A HK1254835A1 HK 1254835 A1 HK1254835 A1 HK 1254835A1 HK 18113929 A HK18113929 A HK 18113929A HK 1254835 A1 HK1254835 A1 HK 1254835A1
Authority
HK
Hong Kong
Prior art keywords
glucose uptake
uptake inhibitors
inhibitors
glucose
uptake
Prior art date
Application number
HK18113929.9A
Other languages
English (en)
Inventor
K‧奧爾塞夫斯基
J-I‧金
M‧波于羅夫斯基
K‧劉
A‧巴索蒂
K‧莫里斯
Original Assignee
卡德門企業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 卡德門企業有限公司 filed Critical 卡德門企業有限公司
Publication of HK1254835A1 publication Critical patent/HK1254835A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18113929.9A 2015-06-26 2018-10-31 葡萄糖攝取抑制劑 HK1254835A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185223P 2015-06-26 2015-06-26
PCT/US2016/039365 WO2016210330A1 (en) 2015-06-26 2016-06-24 Glucose uptake inhibitors

Publications (1)

Publication Number Publication Date
HK1254835A1 true HK1254835A1 (zh) 2019-07-26

Family

ID=57586425

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113929.9A HK1254835A1 (zh) 2015-06-26 2018-10-31 葡萄糖攝取抑制劑

Country Status (8)

Country Link
US (2) US10273248B2 (zh)
EP (1) EP3313825A4 (zh)
JP (1) JP2018518518A (zh)
CN (1) CN108349910A (zh)
CA (1) CA3028355A1 (zh)
EA (1) EA201890153A1 (zh)
HK (1) HK1254835A1 (zh)
WO (1) WO2016210330A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7078960B2 (ja) * 2017-01-26 2022-06-01 エス． トサントリゾス，ヨウラ 置換二環式ピリミジン系化合物および組成物ならびにその使用
US11071735B2 (en) 2017-04-28 2021-07-27 Kadmon Corporation, Llc Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
WO2019001572A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019000682A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US10323023B2 (en) 2017-06-30 2019-06-18 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
US10689386B2 (en) 2018-03-07 2020-06-23 Duquesne University Of The Holy Spirit Pyrazolo[4,3-d]pyrimidines as antitumor agents
US12030857B2 (en) 2018-06-25 2024-07-09 Kadmon Corporation, Llc Glucose uptake inhibitors
WO2021095032A1 (en) * 2019-11-13 2021-05-20 Metabomed Ltd Glucose uptake inhibitors and uses thereof
MX2022006663A (es) * 2019-12-02 2022-07-05 Shanghai Yingli Pharm Co Ltd Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
JP2023534259A (ja) * 2020-07-14 2023-08-08 武漢朗来科技発展有限公司 Ｒｏｃｋ阻害剤及びその製造方法と用途
CN112479913A (zh) * 2020-11-19 2021-03-12 安徽修一制药有限公司 一种n,n-二乙基氯代乙酰胺的制备方法
CN112741828B (zh) * 2021-01-08 2022-04-26 武汉大学 药物联用物及其制备方法和用途
CN117843618A (zh) * 2022-08-29 2024-04-09 北京沐华生物科技有限责任公司 一种ep300/cbp调节剂及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014755A1 (en) * 2002-01-10 2004-01-22 Dhanapalan Nagarathnam Rho-kinase inhibitors
WO2009079412A2 (en) 2007-12-14 2009-06-25 Ardea Biosciences Inc. Reverse transcriptase inhibitors
MX2012004313A (es) * 2009-10-12 2012-07-20 Myrexis Inc Compuestos de amino-pirimidina como inhibidores de cinasa 1 de union a tank (tbk1) y/o i-kappa-b-cinasa epsilon (ikk epsilon).
WO2012040499A2 (en) * 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
PE20140928A1 (es) 2011-04-21 2014-08-24 Origenis Gmbh Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas
CN102901456B (zh) 2012-09-12 2015-10-28 深圳深蓝精机有限公司 检测装置及检测圆轴的外径、跳动值、真圆度的方法
CA2926478C (en) * 2012-10-05 2022-05-24 Kadmon Corporation, Llc Rho kinase inhibitors
US10729691B2 (en) * 2015-06-26 2020-08-04 Kadmon Corporation, Llc Treatment of infectious diseases with glucose uptake inhibitors

Also Published As

Publication number Publication date
WO2016210330A1 (en) 2016-12-29
JP2018518518A (ja) 2018-07-12
EP3313825A4 (en) 2019-03-13
US10988484B2 (en) 2021-04-27
US20180298029A1 (en) 2018-10-18
US10273248B2 (en) 2019-04-30
US20190315772A1 (en) 2019-10-17
CN108349910A (zh) 2018-07-31
CA3028355A1 (en) 2016-12-29
EA201890153A1 (ru) 2018-06-29
EP3313825A1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
HK1254835A1 (zh) 葡萄糖攝取抑制劑
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
HK1258690A1 (zh) 食品改良劑
HK1248089A1 (zh) 止血帶
GB2538731B (en) Methods
DK3373882T3 (en) Patientisolator
EP3156789C0 (en) BIOSENSOR
HK1251621A1 (zh) 生物傳感器
GB201518762D0 (en) Methods
GB201501004D0 (en) Inhibitors
HK1251001A1 (zh) Il-37變體
GB201508927D0 (en) Methods
GB201518047D0 (en) Tourniquets
GB201515655D0 (en) Methods
GB201513390D0 (en) Aortopathy
GB201520949D0 (en) Inhibitors
GB201512609D0 (en) Methods
GB201509839D0 (en) One piece
GB2544782B (en) Solution
GB201521339D0 (en) Methods
GB201517275D0 (en) Biosensor
AU363152S (en) Jewellery
AU363155S (en) Jewellery
AU363151S (en) Jewellery